Prostate cancer
Conditions
Interventions
Suprapubic catheter/Urethral catheter-free group:No urethral catheter will be placed postoperatively
only a suprapubic cystostomy tube will be used for urinary drainage.
urethral catheter group:A transurethral catheter will be placed postoperatively for urinary drainage.
Sponsors
The First Affiliated Hospital of Guangzhou Medical University
Eligibility
Sex/Gender
Male
Age
50 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1.Male patients diagnosed with prostate cancer, aged <= 85 years; 2.Patients who are willing to undergo single-port robot-assisted radical prostatectomy at our hospital, with postoperative urinary drainage via either transurethral catheterization or suprapubic cystostomy; 3.Able to provide written informed consent (ICF) and understand and agree to comply with the study requirements and assessment schedule; 4.Expected survival of more than 2 years; 5.Voluntarily participate in the study, understand its content, sign the informed consent form, and are able to comply with postoperative follow-up and care requirements.
Exclusion criteria
Exclusion criteria: 1.Tumor invasion into adjacent organs or tissues, as identified by preoperative imaging or intraoperative findings, including involvement of the bladder neck, external sphincter, urethra, extensive seminal vesicle invasion, or pelvic wall involvement; 2.Patients diagnosed with any other malignancy within the past 5 years; 3.History of major pelvic or urological surgery, including but not limited to: transurethral resection of the prostate (TURP), bladder incision or cystectomy, urethral reconstruction or complex urethroplasty, pelvic organ resection, or history of pelvic radiotherapy; 4.Known urinary tract structural abnormalities, such as urethral stricture, congenital bladder or urethral malformations, significantly reduced bladder capacity (<100 ml), or ectopic ureteral orifice; 5.Severe bladder dysfunction, including refractory urinary retention, severe overactive bladder or detrusor dysfunction, neurogenic bladder, or previously diagnosed severe urogenital dysfunction syndromes; 6.Long-term use of anticoagulants or antiplatelet agents (anticoagulation discontinued for less than 1 week); 7.Receipt of any form of cancer treatment (surgery, radiotherapy, chemotherapy, endocrine therapy, targeted therapy, or immunotherapy) prior to enrollment blood draw; 8.Presence of other serious systemic diseases that, in the investigator’s opinion, may interfere with the treatment, evaluation, or compliance of the study, including severe disorders of the respiratory, cardiovascular, neurological, psychiatric, gastrointestinal, endocrine, immune, or urinary systems; 9.Participation in another clinical trial or having participated in one that ended within the past year; 10.Cognitive impairment, language or communication disorders, or a history of psychiatric illness that prevents independent understanding and adherence to postoperative catheter management, urinary record-keeping, or follow-up schedules; 11.Refusal to sign the informed consent form or intraoperative conversion to open surgery or an alternative drainage method.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative Pain Score;Urinary Continence Rate;Incidence of Postoperative Complications; | — |
Secondary
| Measure | Time frame |
|---|---|
| Length of Hospital Stay;Incidence of Urethral Stricture; | — |
Countries
China
Contacts
Public ContactGuohua Zeng; Di Gu
The First Affiliated Hospital of Guangzhou Medical University
Outcome results
None listed